Gefarnate (CAS 51-77-4) Global Market Research Report 2024

About the Gefarnate Market

Gefarnate is a type of gastrointestinal drug used to treat a variety of gastrointestinal disorders, including irritable bowel syndrome, ulcerative colitis, and Crohn's disease. It is a prodrug of mesalamine, which is an anti-inflammatory drug used to reduce inflammation in the gastrointestinal tract. Gefarnate is available in both oral and rectal formulations, and is typically prescribed for short-term use. It is generally well-tolerated, with few side effects. The Gefarnate market is a rapidly growing segment of the gastrointestinal drug market. It is estimated that the global market for Gefarnate is expected to reach $1.2 billion by 2027. The market is driven by the increasing prevalence of gastrointestinal disorders, the growing demand for effective treatments, and the availability of generic versions of the drug. Some of the major companies in the Gefarnate market include AstraZeneca, Pfizer, Merck, Novartis, and GlaxoSmithKline. These companies are actively involved in the development and marketing of Gefarnate products. Show Less Read more